A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer
about
Applications of targeted proteomics in systems biology and translational medicineEmerging proteomic technologies for elucidating context-dependent cellular signaling events: A big challenge of tiny proportionsTargeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patientsApproaches for defining the Hsp90-dependent proteome.Oxidized lipids block antigen cross-presentation by dendritic cells in cancerEvaluating melanoma drug response and therapeutic escape with quantitative proteomicsCPTAC Assay Portal: a repository of targeted proteomic assays.The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsBody fluid identification by mass spectrometry.Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patientsMonitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.Evaluation of direct infusion-multiple reaction monitoring mass spectrometry for quantification of heat shock proteins.Implementation of proteomic biomarkers: making it work.Evaluation of protein quantification using standard peptides containing single conservative amino acid replacementsFibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane.Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics AssaysDemonstrating the feasibility of large-scale development of standardized assays to quantify human proteins.Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometryTargeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach.A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research.Integration of proteomics into systems biology of cancer.Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins.MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum.Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins.Quantitative proteomics of breast tumors: Tissue quality assessment to clinical biomarkers.Clinical applications of MS-based protein quantification.Study of phosphorylation events for cancer diagnoses and treatment.Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis.Network views for personalized medicine.Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors.Proteomic Profiling of Hsp90 Inhibitors.Matrix metalloproteinase processing of PTHrP yields a selective regulator of osteogenesis, PTHrP1-17.Structure-informed detection and quantification of peptides in food and biological fluids
P2860
Q26852271-BA899C95-A41D-466A-92E3-50C4DD2BF9FBQ28081956-20F2A3F1-40C4-42B7-82F0-27EF5F235DB7Q28085015-BE2FDEAD-EDE8-4ED8-B1BF-C3B6CA53A557Q28247643-0AB1D211-2B8F-4D9A-9F29-18062C60A4DAQ28384581-3A79536C-BDC7-45AB-A74D-885E2B20CA2DQ33850665-721B8544-76EC-4F0E-BE70-D976F3440DEEQ33960135-FEF1CC7B-E36F-4974-B640-6810C6B92322Q34165045-B765EA2E-DE44-417F-BE25-1F2842AE52B9Q34633625-9D534620-F230-45EF-A05B-DC3B25758DC3Q34997502-50180ABE-F49A-49CF-844D-06D88FC0233BQ35579598-ED8BE337-7349-4EA2-8461-45707B8F76A1Q35903689-F5A62D4F-BF8E-4EE4-820B-13C15BB49D53Q36297774-3DD3551B-72FA-46F0-881E-3C2709EA012FQ36301398-58F5B3D0-B133-43E1-A77D-049535CA5E68Q36373537-ACA44E8A-7555-42EB-BB7C-58D3FFDD59A1Q36379619-D71C3859-60FE-4F46-BA9F-5C40723743E9Q36931453-EB9AB3D9-6D93-4702-84CC-083A599AE41BQ37244496-DEAC2EA9-9A08-4529-9F29-66F9567C124BQ37580083-B802A04B-15FB-45EB-B549-47C014C066A4Q37618631-E5F9E2B0-0BFC-46D6-BE38-DA18191A9569Q37623655-2CDB9D99-E0B9-4751-ABC8-51DB3B592865Q37651691-54F9C6F3-EE48-4397-B2E7-553118E391ABQ37992554-98B0CEF2-EC3E-44DC-B50C-ECE6CDA8ACC0Q38009277-6D32812B-16D4-4C1A-B4BE-83D8544A0D84Q38183147-44A8B0E3-6ED3-4FF4-8FC8-AE4CAE73794BQ38203040-510EFB01-4824-4FFC-88CD-BA930938F2B9Q38694892-15EA40BE-F724-41B1-B0E7-A034E3BFD052Q38719192-3AD0CF1E-1C07-456D-B19A-57D3FC17FD2FQ38802991-ADFF7A2F-18F0-41B5-9454-C6151CE8D8C9Q40857065-4680FE7B-0FDB-488E-946F-5916BB694FD7Q41612097-B14B66C2-DFFB-4202-A478-BB53C554E7CAQ42694013-A94C5C3D-ACFF-4B84-B9B2-D122C29D98D8Q47291460-001964DC-EAFA-4FAE-B560-7CED9F260833Q47362623-06B6C20E-7DF5-4C92-971B-5A6DABA3A617Q51075730-80BBF331-67F0-4380-962C-916ADC4B22BAQ58230793-7C88EAD0-FDE0-48CB-8A7F-0FED091D3414
P2860
A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A database of reaction monitor ...... therapeutic response in cancer
@ast
A database of reaction monitor ...... therapeutic response in cancer
@en
type
label
A database of reaction monitor ...... therapeutic response in cancer
@ast
A database of reaction monitor ...... therapeutic response in cancer
@en
prefLabel
A database of reaction monitor ...... therapeutic response in cancer
@ast
A database of reaction monitor ...... therapeutic response in cancer
@en
P2093
P2860
P356
P1476
A database of reaction monitor ...... therapeutic response in cancer
@en
P2093
C Eric Thomas
David Shibata
Elizabeth R Remily-Wood
Eric Haura
Gregory C Bloom
Guolin Zhang
Javier Pinilla-Ibarz
Jeffrey Lancet
Joana E Ochoa
P2860
P304
P356
10.1002/PRCA.201000115
P577
2011-06-08T00:00:00Z